Anda Biologics Secures Tens of Millions in Series A Funding to Advance AI-Driven Personalized Cancer Vaccines

At the start of the new year, the field of precision oncology has witnessed a breakthrough. ANDA BIOPHARMA (Shenzhen) Co., Ltd. (hereinafter referred to as "ANDA BIOPHARMA") announced the completion of its Series A financing round, raising tens of millions of yuan. The round was led by LEADING CAPITAL and PuXin Capital, with participation from Linchuang Sinan, Botong Venture Capital, Draper Fisher Jurvetson Longmai, and other institutions. The funds raised will be primarily used to advance the clinical research of its core pipeline product, the personalized cancer neoantigen vaccine PCNAT-01, while accelerating the preclinical development of other projects in the pipeline. This financing not only demonstrates the capital market's recognition of ANDA BIOPHARMA's technological innovation capabilities but also marks a critical step forward for China in the field of personalized cancer therapy.

ANDA BIOPHARMA is one of the earliest teams in China to pioneer personalized tumor neoantigen therapy. As a global leader in AI-driven tumor neoantigen therapies, the company has developed the "AD-INN" technical analysis platform through "deep learning + multi-omics integration." By integrating single-cell sequencing, organoid-on-chip, and digital twin technologies, ANDA BIOPHARMA has achieved an intelligent, closed-loop R&D process covering everything from neoantigen discovery to vaccine potency validation. As a biopharmaceutical company focused on developing First-in-class innovative drugs, ANDA BIOPHARMA has continued to achieve breakthroughs in the treatment of solid tumors: its core product, PCNAT-01 (a personalized neoantigen vaccine for pancreatic cancer), received Orphan Drug Designation (ODD) from the U.S. FDA in March 2022, becoming the first globally recognized personalized vaccine project for pancreatic cancer; it obtained FDA approval for clinical trials in October 2024; and received clinical trial approval from the National Medical Products Administration (NMPA) in March 2025.

Professor Hu Landian, Chairman, Founder, and CEO of ANDA BIOPHARMA, stated:“The successful completion of this financing round, coupled with the simultaneous submission of clinical trial applications in both China and the United States, marks ANDA BIOPHARMA’s official transition from preclinical research to clinical development. With the closing of this round, ANDA BIOPHARMA will continue to deepen its strategic layout of an integrated precision oncology healthcare system encompassing prevention, diagnosis, treatment, and management. Standing at this new starting point, we will accelerate the advancement of our Tumor Immune Digital Twin Initiative and expedite clinical-stage studies to bring our products to market sooner, thereby benefiting more patients.”

Mr. Wu Chaoyang, Chairman of LEADING CAPITAL, stated:“We are delighted to participate in this round of financing for ANDA BIOPHARMA. As is well known, immunotherapy, as one of the key directions in anti-tumor treatment, has continued to achieve breakthroughs in recent years. The approval and market launch of representative drugs such as immune checkpoint inhibitors, CAR-T, TCR-T, and TILs have benefited a growing number of patients, signifying continuous progress in humanity’s fight against malignant tumors. We have observed that tumor neoantigen vaccine drugs, as an important representative of anti-tumor immunotherapies, have also yielded exciting clinical results, prompting extensive strategic deployments by global multinational corporations (MNCs). ANDA BIOPHARMA is among the earliest teams in China to pursue personalized tumor neoantigen therapy. Its technology platform, built on single-cell sequencing and artificial intelligence algorithms, enables precise prediction of tumor neoantigens while significantly improving the accuracy of immunogenicity assessment. In clinical practice, tumor neoantigen vaccines developed based on this platform have achieved impressive results in investigator-initiated trials (IITs), demonstrating the significant potential of this pipeline. As an investment institution focused on early-stage biopharmaceuticals, we are highly optimistic about ANDA BIOPHARMA’s future prospects in the field of tumor neoantigen vaccines. We look forward to the company accelerating its pipeline development and achieving product commercialization at the earliest opportunity, thereby bringing benefit to patients worldwide.”

Ms. Cai Wen, Chairperson of PuXin Capital, stated:“ANDA BIOPHARMA demonstrates remarkable innovation and potential in the field of personalized neoantigen therapy for cancer. As the first personalized vaccine to receive FDA Orphan Drug Designation (ODD) for pancreatic cancer treatment globally, PCNAT-01 has achieved world-leading progress and significant breakthroughs in clinical research for pancreatic cancer. Furthermore, it has shown potential efficacy against other solid tumors. ANDA BIOPHARMA’s research achievements in tumor neoantigen prediction place it at the forefront of global oncology treatment. We believe this investment will accelerate the company’s development, drive innovative breakthroughs in cancer therapy, and bring new hope to patients worldwide. PuXin Capital will continue to monitor and support frontier innovations in medical technology, fostering the emergence of biopharmaceutical enterprises with global competitiveness.”

Ms. Zhao Xiaoyun, Project Leader of Linchuang Sinan, stated:“ANDA BIOPHARMA has made remarkable progress in the personalized precision treatment of solid tumors. Leveraging years of robust scientific research, the company has established a leading AI-based antigen prediction and validation platform. Its pipeline for preventing postoperative recurrence in pancreatic cancer has achieved multiple milestones, successfully completing the investigator-initiated clinical trial with the largest patient enrollment globally. Demonstrating significant clinical value, this achievement underscores ANDA BIOPHARMA’s potential to deliver greater impact in the field of solid tumor therapy, ultimately benefiting a broad population of patients.”

Mr. Li Xiaoping, Chairman of Botong Venture Capital, stated:“ANDA BIOPHARMA has accumulated years of expertise in the field of bioinformatics and is dedicated to neoantigen therapies for solid tumors, achieving world-leading therapeutic outcomes. In participating in ANDA BIOPHARMA’s financing round, Botong Ventures not only provides financial support but also introduces an AI project team composed of ‘National Outstanding Engineers’ to collaborate with ANDA BIOPHARMA on developing more advanced AI tools for drug discovery. This initiative marks Botong Ventures’ most recently completed exclusive angel investment. Through this synergistic partnership, we aim to help ANDA BIOPHARMA achieve new milestones in oncology treatment, maintain its industry leadership, and become a globally renowned biopharmaceutical company as soon as possible.”

Mr. Li Dechun, Partner at Draper Dragon, stated:“We are highly optimistic about ANDA BIOPHARMA’s technological innovation capabilities in the field of personalized precision oncology. Its core product, PCNAT-01, has achieved several significant milestones globally as the first personalized neoantigen vaccine for pancreatic cancer, fully demonstrating the team’s technical barriers in AI-driven neoantigen vaccine development. We look forward to the company continuing to leverage its technological advantages, integrating cutting-edge approaches such as AI and big data, to provide patients with more precise and efficient treatment solutions, thereby propelling personalized cancer immunotherapy to new heights.”

ANDA BIOPHARMA, established in 2018 and registered in Shenzhen, is a biotechnology company dedicated to the research and development of personalized tumor neoantigen vaccines. The company was co-founded by senior overseas-returnee professors from the Chinese Academy of Sciences, together with leading experts in tumor genomics, immunology, vaccinology, and clinical medicine. ANDA BIOPHARMA operates multiple technology platforms, including tumor neoantigen sequencing, neoantigen identification and prediction, in vitro potency testing of personalized tumor neoantigen vaccines, and in vivo efficacy monitoring of such vaccines. Its lead candidate, PCNAT-1, has successfully achieved dual regulatory filings in both China and the United States. Furthermore, PCNAT-1 has received FDA Orphan Drug Designation, making it the first pipeline globally to obtain this designation in its field.

The Guangxi Nanwan Baiao Venture Capital Fund is a fund initiated and managed by Leading Capital, focusing on early-stage investments in the biopharmaceutical sector. Established in 2007, Leading Capital is a professional investment fund management institution and a comprehensive investment management group. The total assets under management (AUM) of Leading Capital exceed RMB 30 billion. It has completed investments in over 100 projects, with nearly 30 portfolio companies successfully listed on stock exchanges in Shanghai, Shenzhen, and Hong Kong, and many have become industry leaders. Leading Capital engages in close collaboration with domestic industrial leaders and high-quality listed companies, supporting them through the joint establishment of industrial investment funds and co-investments. By conducting continuous and in-depth industrial investments and mergers and acquisitions, it aims to build a healthy industrial ecosystem. Through venture capital (VC), growth equity (PE), and buyouts, Leading Capital helps leading companies integrate various resources, enhance their technological capabilities, expand market boundaries and scope, and support their sustained growth and competitiveness.

As a specialized equity investment platform under Shanghai Trust, PuXin Capital has always adhered to the philosophy of "long-term value investment." Taking the cultivation of new quality productive forces as its mission, the firm deeply integrates into national strategies for technological innovation and the development of a modern industrial system. The company has established three strategic investment matrices: "Hard Tech & Intelligent Manufacturing," "Digitalization & Enterprise Services," and "Life Health & Medical Services," supported by a professional investment team and a comprehensive investment management framework. Through deep integration of industrial chains and the construction of ecosystem value, PuXin Capital has mobilized over RMB 10 billion in capital to serve the real economy, helping more than 30 biopharmaceutical companies achieve technological breakthroughs and industrial upgrading.

The Linchuang Sinan Fund is a market-oriented sci-tech innovation incubation fund initiated and established by the Lingang Group, dedicated to serving early-stage sci-tech enterprises by building a comprehensive technology incubation system. Focusing on frontier technology sectors and targeting industries with long-term growth potential and substantial barriers to entry, the Linchuang Sinan Fund incubates and nurtures innovative enterprises to foster an industrial innovation ecosystem. In the life sciences sector, the fund prioritizes investment in and incubation of early-stage innovative pharmaceuticals, high-end medical devices, advanced biotechnology, and consumer healthcare, thereby providing effective empowerment to startups.

The Youda Haihe Biopharmaceutical Venture Capital Fund is a venture capital fund invested in by the Tianjin Angel Fund of Funds and the Tianjin Wuqing Development Zone, dedicated to investing in biotechnology enterprises with internationally leading technological capabilities. The fund manager, Botong Ventures, has core partners who have led or participated in dozens of investment projects, with cumulative assets under management exceeding RMB 10 billion. In recent years, the firm has deeply cultivated the fields of biotechnology and artificial intelligence, adhering to its proprietary “capital-industry double helix” model integrated with an industry expert think tank to create a precise decision-making engine for technology investments. This approach has earned high recognition from the government, industry sectors, investors, and portfolio companies.

Qingdao Draper Fisher Jurvetson Longmai Fund is an investment fund under DFJ DragonFund, focusing on the life and health sector. It concentrates on early-stage investments and industrial layout in frontier areas such as innovative pharmaceuticals, high-end medical devices, and digital healthcare. Leveraging globally leading technological foresight and industrial resources, the fund continuously monitors disruptive technological changes in the life sciences, facilitating the translation of cutting-edge technologies from laboratory research to clinical applications, thereby driving industry innovation and upgrading.DFJ DragonFund was co-founded in 2006 by globally influential venture capitalists and China’s first generation of venture capitalists. It is a member fund and governing council member of the Draper Venture Network (DVN), a global network of early-stage venture capital funds. DFJ DragonFund manages multiple US dollar and RMB private equity funds, specializing in early-stage investments in next-generation information technology, life and health technologies, and hard-core technologies, and has successfully incubated numerous well-known enterprises.